Apellis Pharmaceuticals granted E.U. orphan drug designation for APL-2 in PNH May 10, 2017 No Comments
Interim results from phase III HAVEN 2 pediatric trial of emicizumab in hemophilia A April 18, 2017 No Comments
RSS